News AI in drug discovery and development: news watch Recent developments in the biopharma AI world include a big financing for Verily, and updates from Zealand, Latent Labs, Insilico, and BMS/insitro.
News MSD taps Quotient for IBD drug targets in $2.2bn deal MSD is paying $20m upfront to activate an alliance with Flagship's Quotient Therapeutics to find new targets in inflammatory bowel disease.
News JPM: Illumina launches 'unprecedented' disease biology atlas Illumina says its new Billion Cell Atlas can be used to identify and validate drug targets and train AI models used in drug discovery.
News Lab-in-a-loop specialist Relation attracts Novartis alliance UK-based AI and multi-omics company Relation Therapeutics will seek out targets for allergic diseases on behalf of Novartis in a $1.7bn-plus alliance.
News AstraZeneca joins Tempus, Pathos in cancer AI project AstraZeneca has started work with Tempus and Pathos AI on a $200m project to build a comprehensive multimodal foundation model for oncology.
News CRUK scientists find new tool to test lung cancer therapies Researchers in the UK have developed a lung cancer cell line that they believe could be an important new tool for the discovery of new therapies.
News AbbVie tries a new approach in 340B programme battle AbbVie has opened a new front in the pharma industry's efforts to reform the 340B drug discounting programme for safety net hospitals in the US.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.